当前位置： SCI文献检索 > CARDIOVASCULAR DRUGS AND THERAPY期刊下所有文献 > Recombinant human interleukin-1 receptor antagonist provides cardioprotection during myocardial ischemia reperfusion in the mouse.

Recombinant human interleukin-1 receptor antagonist provides cardioprotection during myocardial ischemia reperfusion in the mouse.

Abstract：

PURPOSE:Acute myocardial infarction (AMI) drives an intense inflammatory response that contributes to infarct healing and cardiac remodeling. Recently, different studies have identified a role of interleukin-1 (IL-1) in the development of adverse cardiac remodeling. However, in animal models of AMI IL-1 has been shown to be cardioprotective in preconditioning, raising the question of clinical safety of therapeutic IL-1 blockade for autoinflammatory diseases or for the prevention or the treatment of AMI. In this study we proposed to evaluate the effects of pretreatment with recombinant human interleukin-1 receptor antagonist (rhIL-1Ra) on ischemia reperfusion (I/R) injury to the heart. METHODS:RhIL-1Ra was given 4 h or 30 min before the surgical induction of I/R. Left ventricular ejection fraction(LVEF) and infarct size were assessed to determine the effects of the drug pretreatment compared to vehicle treated mice. RESULTS:RhIL-1Ra, given 4 h or 30 min before the onset of the ischemia, showed marked cardioprotection though preservation of the LVEF (no change vs sham operated mice) and the reduction of the infarct size (-40 % vs vehicle-treated mice). No differences were observed between the two groups of rhIL-1Ra treatment. CONCLUSIONS:IL-1 blockade therapies using rhIL-1Ra prior the onset of AMI protects the myocardium and preserves cardiac function.

journal_name

Cardiovasc Drugs Ther

journal_title

Cardiovascular drugs and therapy

authors

Toldo S,Schatz AM,Mezzaroma E,Chawla R,Stallard TW,Stallard WC,Jahangiri A,Van Tassell BW,Abbate A

doi

10.1007/s10557-012-6389-x

subject

Has Abstract

pub_date

2012-06-01 00:00:00

pages

273-6

issue

3

eissn

0920-3206

issn

1573-7241

journal_volume

26

pub_type

杂志文章

相关文献

CARDIOVASCULAR DRUGS AND THERAPY文献大全
  • KT-362 related effects on intracellular calcium release and associated clinical potential: arrhythmias, myocardial ischemia, and hypertension.

    abstract：:The following discourse addresses the pharmacologic profile of KT-362, its clinical potential as an anti-arrhythmic agent with associated hypotensive effects, as well as its additional related potential in myocardial ischemia and related sequellae, and the specific cellular actions that may be responsible for these po...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章,评审

    doi：10.1007/BF02018262

    authors： Hester RK,Shibata S

    更新日期：1990-10-01 00:00:00

  • The costs of treating hypertension.

    abstract：:Recent surveys in the U.S. have reported, for the first time, that a significant number of patients with hypertension are finding that the cost of medication and treatment in general is an obstacle to treatment. The cost of management of hypertension can be contained if: a) the diagnostic workup is kept simple (this d...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/BF01857624

    authors： Moser M

    更新日期：1989-10-01 00:00:00

  • Levosimendan in Acute and Advanced Heart Failure: an Expert Perspective on Posology and Therapeutic Application.

    abstract：:Levosimendan, a calcium sensitizer and potassium channel-opener, is widely appreciated by many specialist heart failure practitioners for its effects on systemic and pulmonary hemodynamics and for the relief of symptoms of acute heart failure. The drug's impact on mortality in large randomized controlled trials has be...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章,评审

    doi：10.1007/s10557-018-6838-2

    authors： Bouchez S,Fedele F,Giannakoulas G,Gustafsson F,Harjola VP,Karason K,Kivikko M,von Lewinski D,Oliva F,Papp Z,Parissis J,Pollesello P,Pölzl G,Tschöpe C

    更新日期：2018-12-01 00:00:00

  • Combination Therapy of Pulmonary Arterial Hypertension with Vardenafil and Macitentan Assessed in a Human Ex Vivo Model.

    abstract：PURPOSE:Treatment of pulmonary arterial hypertension (PAH) by vasodilator drug monotherapy is often limited in its effectiveness. Combination therapy may help to improve treatment and to reduce drug toxicity. This study assessed the combination of the endothelin receptor antagonist macitentan and the phosphodiesterase-...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/s10557-019-06868-y

    authors： Hoenicka M,Golovchenko S,Englert L,Spaeth M,Shoshiashvili L,Großer C,Hofmann HS,Ried M

    更新日期：2019-06-01 00:00:00

  • Cytotoxicity of amiodarone in cultured human endothelial cells.

    abstract：:As damage to the pulmonary vascular endothelium may be responsible for the lung toxicity of amiodarone, we evaluated the cytolytic toxicity of the drug in cultures of endothelial cells. Cells were cultured from human umbilical cord veins. Amiodarone caused a vacuolization of the cells with liberation of both lactate d...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/BF00050996

    authors： Baudin B,Bénéteau-Burnat B,Giboudeau J

    更新日期：1996-11-01 00:00:00

  • Exendin-4 Attenuates Remodeling in the Remote Myocardium of Rats After an Acute Myocardial Infarction by Activating β-Arrestin-2, Protein Phosphatase 2A, and Glycogen Synthase Kinase-3 and Inhibiting β-Catenin.

    abstract：PURPOSE:This study tested if the protective anti-remodeling effect of GLP-1 agonist Exendin-4 after an acute myocardial infarction (MI) in rats involves inhibition of the Wnt1/β-catenin signaling pathway. METHODS:Rats were divided into sham, sham + Exendin-4 (10 μg/day, i.p), MI, and MI + Exendin-4. MI was introduced ...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/s10557-020-07006-9

    authors： Eid RA,Khalil MA,Alkhateeb MA,Eleawa SM,Zaki MSA,El-Kott AF,Al-Shraim M,El-Sayed F,Eldeen MA,Bin-Meferij MM,Awaji KME,Shatoor AS

    更新日期：2020-05-30 00:00:00

  • Effects of trimetazidine on in vivo coronary arterial platelet thrombosis.

    abstract：:We used Folts' model of critical coronary artery stenosis with endothelial damage, which measures platelet-rich thrombus accumulation from cyclic flow reductions (CFRs). This paper reports results applied to trimetazidine, a member of the piperazine group. Trimetazidine at a dose of 1 mg/kg completely abolished CFRs c...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/BF00878324

    authors： Belcher PR,Drake-Holland AJ,Hynd JW,Noble MI

    更新日期：1993-02-01 00:00:00

  • Effects of Dipeptidyl Peptidase-4 Inhibitor Linagliptin on Left Ventricular Dysfunction in Patients with Type 2 Diabetes and Concentric Left Ventricular Geometry (the DYDA 2™ Trial). Rationale, Design, and Baseline Characteristics of the Study Population.

    abstract：PURPOSE:A multicentre, randomized, double-blind, placebo-controlled, parallel-group study aimed to define the potential positive effect of dipeptidyl peptidase-4 inhibition on left ventricular systolic function (LVSF) beyond glycemic control in type 2 diabetes mellitus (T2DM) (DYDA 2™ trial). METHODS:Individuals with ...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/s10557-019-06898-6

    authors： Giorda CB,Cioffi G,Lucci D,Nada E,Ognibeni F,Mancusi C,Latini R,Maggioni AP,DYDA 2 Investigators.

    更新日期：2019-10-01 00:00:00

  • Effects of almokalant, a class III antiarrhythmic agent, on supraventricular, reentrant tachycardias. Almokalant Paroxysmal Supraventricular Tachycardia Study Group.

    abstract：:The aim of the present study was to investigate the effects of almokalant on sustained reentrant supraventricular tachycardias. Reentrant tachycardias were induced, using transesophageal atrial stimulation, in 82 patients with atrioventricular reentrant tachycardia (n = 54) or AV nodal reentrant tachycardia (n = 28). ...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 临床试验,杂志文章

    doi：10.1023/a:1007761825414

    authors： Darpö B,Edvardsson N

    更新日期：1997-07-01 00:00:00

  • Influence of the new class I antiarrhythmic agent diprafenone on the end-systolic pressure-volume relationship (conductance technique).

    abstract：:To evaluate cordiodepressive risks of antiarrhythmic treatment with diprafenone, we monitored, in addition to conventional hemodynamic parameters, end-systolic pressure-volume relations to assess potential negative inotropic effects. Thirteen patients underwent hemodynamic analysis with and without the influence of di...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/BF01883858

    authors： Thormann J,Kramer W,Kremer P,Schlepper M

    更新日期：1989-04-01 00:00:00

  • Regression of left ventricular hypertrophy and improvement of renal hemodynamics in hypertensive patients treated with quinapril.

    abstract：:Of 17 patients with mild to moderate essential hypertension, 8 showed echocardiographic evidence of left ventricular hypertrophy. Cardiac and renal function evaluated by glomerular filtration rate (GFR) were studied in all patients before and after 20 weeks of quinapril treatment. Systolic pressure decreased from 174....

    journal_title：Cardiovascular drugs and therapy

    pub_type： 临床试验,杂志文章

    doi：10.1007/BF00877120

    authors： De Caprio L,De Rosa ML,Di Palma A,Lirato C,Caccese P,Sestito M,Lastoria S,Cicatiello AM,Rengo F

    更新日期：1994-10-01 00:00:00

  • Effect of an educational program (PEGASE) on cardiovascular risk in hypercholesterolaemic patients.

    abstract：BACKGROUND:Many studies have demonstrated a gap between guidelines for the prevention of cardiovascular disease (CVD) and their implementation in clinical practice. AIM:The PEGASE education program has been devised with an aim to improve the management of patients at high risk of CVD. METHODS:In a multicentre study c...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s10557-008-6137-4

    authors： Bruckert E,Giral P,Paillard F,Ferrières J,Schlienger JL,Renucci JF,Abdennbi K,Durack I,Chadarevian R,PEGASE group.

    更新日期：2008-12-01 00:00:00

  • Effects of altered extracellular potassium and pacing cycle length on the class III antiarrhythmic actions of dofetilide (UK-68,798) in guinea-pig papillary muscle.

    abstract：:The effects of altered extracellular K+ concentrations ([K+]o) and pacing cycle lengths (CLs) on the electrophysiological actions of dofetilide (UK-68,798), a potent class III antiarrhythmic agent, were examined in isolated guinea-pig ventricular papillary muscle. At a normal [K+]o (4 mM) and at CL between 300 and 500...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/BF00054193

    authors： Yang T,Tande PM,Lathrop DA,Refsum H

    更新日期：1992-08-01 00:00:00

  • Diuretics and cation transport in hypertensive blacks.

    abstract：:Thiazide diuretics are particularly efficacious in the treatment of hypertension in blacks. A number of observations suggest that many hypertensive blacks have features consistent with a status of "corrected" volume expansion. Our studies, as well as those of other investigators, show that the Na,K pump is inhibited i...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章,评审

    doi：10.1007/BF02603181

    authors： Quintanilla AP,Wagener OE

    更新日期：1990-03-01 00:00:00

  • Effects of short- and long-term administration of nifedipine on serum lipoprotein metabolism in patients with mild hypertension.

    abstract：:The effects of short- and long-term administration of nifedipine on serum lipids, lipoproteins, and apolipoproteins (apo) were studied. Administration of nifedipine capsule for 4 months significantly decreased triglycerides and increased the HDL2 cholesterol and the HDL2/HDL3 cholesterol ratio. No significant changes ...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 临床试验,杂志文章

    doi：10.1007/BF02018313

    authors： Sasaki J,Arakawa K

    更新日期：1990-08-01 00:00:00

  • Predicting response to chronic antihypertensive treatment with fosinopril: the role of angiotensin-converting enzyme gene polymorphism.

    abstract：:Insertion (I)/deletion (D) polymorphism of the ACE gene has been reported to be involved in various cardiovascular diseases. We investigated prospectively whether the response to the ACE inhibitor fosinopril varied according to the ACE genotype in previously untreated Greek hypertensive patients. After a 4-week observ...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1023/a:1007820401377

    authors： Stavroulakis GA,Makris TK,Krespi PG,Hatzizacharias AN,Gialeraki AE,Anastasiadis G,Triposkiadis P,Kyriakidis M

    更新日期：2000-08-01 00:00:00

  • Mitochondrial-Shaping Proteins in Cardiac Health and Disease - the Long and the Short of It!

    abstract：:Mitochondrial health is critically dependent on the ability of mitochondria to undergo changes in mitochondrial morphology, a process which is regulated by mitochondrial shaping proteins. Mitochondria undergo fission to generate fragmented discrete organelles, a process which is mediated by the mitochondrial fission p...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章,评审

    doi：10.1007/s10557-016-6710-1

    authors： Ong SB,Kalkhoran SB,Hernández-Reséndiz S,Samangouei P,Ong SG,Hausenloy DJ

    更新日期：2017-02-01 00:00:00

  • Functional antagonism of different angiotensin II type I receptor blockers in human arteries.

    abstract：OBJECTIVES:To evaluate and compare the functional type and the degree of antagonism of the selective angiotensin II type 1 receptor blockers (ARB) losartan, EXP 3174 (the active metabolite of losartan), valsartan and candesartan in human internal mammary arteries. METHODS:Human internal mammary arteries were obtained ...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1023/a:1021729909456

    authors： Wagenaar LJ,Voors AA,Buikema H,van Buiten A,Lübeck RH,Boonstra PW,van Veldhuisen DJ,van Gilst WH

    更新日期：2002-07-01 00:00:00

  • Onset of action of captopril, enalapril, enalaprilic acid and lisinopril in normal man.

    abstract：:The effects of orally administered captopril, enalapril and lisinopril on plasma concentrations of angiotensin converting enzyme (ACE), angiotensin II (ANGII) and renin (PRC) were studied over a period of 6 hours in 6 normal subjects. A further 4 subjects received intravenous enalapril and enalaprilic acid (enalaprila...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/BF02125832

    authors： Semple PF,Cumming AM,Meredith PA,Morton JJ

    更新日期：1987-01-01 00:00:00

  • Left ventricular mass changes with nicardipine therapy in essential hypertension.

    abstract：:Eighteen hypertensive patients (13 males, 5 females; age 48 +/- 13; diastolic blood pressure greater than 95 mmHg), either previously untreated or who had been off treatment for more than 3 months, underwent M-mode echocardiography before (DO) and after (D90) 3 months of nicardipine therapy (60-90 mg/day). All echocar...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 临床试验,杂志文章

    doi：10.1007/BF01865511

    authors： Gosse P,Lacroix P,Roudaut R,Dallocchio M

    更新日期：1989-08-01 00:00:00

  • Vascular complications in hypertension: the VHAS study. Verapamil-Hypertension Atherosclerosis Study.

    abstract：:The VHAS (Verapamil-Hypertension Atherosclerosis Study) Investigators entered 1464 patients with essential hypertension and blood pressure (BP) values > or = 160 mmHg systolic and 95 mmHg diastolic (DBP) but excluded those with a DBP > or = 115 mmHg, and those with diabetes mellitus or previous myocardial infarction o...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1007/BF00877865

    authors： Zanchetti A

    更新日期：1995-08-01 00:00:00

  • Alterations in the prognosis of chronic heart failure: an overview of the major mortality trials.

    abstract：:Treatment of chronic heart failure (CHF) remains a major medical problem. Although in the last decades the benefits of several therapies in different patient populations with left ventricular dysfunction have been established, morbidity and mortality of CHF patients are high. Consequently, in the last decade improveme...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章,meta分析

    doi：10.1023/a:1007786019054

    authors： Szabó BM,van Veldhuisen DJ,de Graeff PA,Lie KI

    更新日期：1997-07-01 00:00:00

  • The applied pharmacology of beta-adrenoceptor antagonists (beta blockers) in relation to clinical outcomes.

    abstract：:Despite the fact that beta blockers were introduced into clinical practice 25 years ago, new beta blockers with differing kinetic and dynamic profiles continue to be developed and marketed. This overview assesses some of the more extensively studied agents from the point of view of proof of utility and the validity of...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章,评审

    doi：10.1007/BF03029726

    authors： Fitzgerald JD

    更新日期：1991-06-01 00:00:00

  • Acute effects of celiprolol on angiographically normal and stenotic coronary arteries.

    abstract：:Unselective and beta 1-selective beta-blockers may induce vasoconstriction of normal and stenotic epicardial coronary arteries. To analyze the influence of the "vasodilatory" beta-blocker celiprolol on coronary vasomotility, 0.4 mg celiprolol/kg were intravenously infused over 4 minutes in 13 patients with coronary ar...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 临床试验,杂志文章

    doi：10.1023/a:1007780713915

    authors： Jost S,Hausmann D,Lippolt P,Sturm M

    更新日期：1997-04-01 00:00:00

  • Ranolazine treatment for myocardial infarction? Effects on the development of necrosis, left ventricular function and arrhythmias in experimental models.

    abstract：:Ranolazine, an inhibitor of the late current of the cardiac action potential (late I(Na)), is a well established clinical treatment for chronic angina. The late INa in cardiac myocytes also plays an important role in the pathophysiology of acute myocardial ischemia and reperfusion, and thus is a potential therapeutic ...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章,评审

    doi：10.1007/s10557-014-6548-3

    authors： Hale SL,Kloner RA

    更新日期：2014-10-01 00:00:00

  • Myocardial ischemia and reperfusion: the role of oxygen radicals in tissue injury.

    abstract：:Thrombolytic therapy has gained widespread acceptance as a means of treating coronary artery thrombosis in patients with acute myocardial infarction. Although experimental data have demonstrated that timely reperfusion limits the extent of infarction caused by regional ischemia, there is growing evidence that reperfus...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章,评审

    doi：10.1007/BF00133206

    authors： Werns SW,Lucchesi BR

    更新日期：1989-01-01 00:00:00

  • Porcine heparin increases postoperative bleeding in cardiopulmonary bypass patients.

    abstract：:One hundred thirteen patients undergoing cardiopulmonary bypass were randomly assigned to receive either bovine or porcine heparin. Heparin was infused at 4.5 mg/kg during bypass and administered at the lesser of 70 units/kg or 5000 units/dose at 12-hour intervals postoperatively. Platelet counts decreased to 45% of p...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1007/BF01857644

    authors： Iverson LI,Duhaylongsod FG,Young JN,Ecker RR,Ennix CL Jr,Moretti RL,Farrar M,Hayes R,Lee J,May IA

    更新日期：1990-02-01 00:00:00

  • Preservation of Glucagon-Like Peptide-1 Level Attenuates Angiotensin II-Induced Tissue Fibrosis by Altering AT1/AT 2 Receptor Expression and Angiotensin-Converting Enzyme 2 Activity in Rat Heart.

    abstract：PURPOSE:The glucagon-like peptide-1 (GLP-1) has been shown to exert cardioprotective effects in animals and patients. This study tests the hypothesis that preservation of GLP-1 by the GLP-1 receptor agonist liraglutide or the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin is associated with a reduction of angiote...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/s10557-015-6592-7

    authors： Zhang LH,Pang XF,Bai F,Wang NP,Shah AI,McKallip RJ,Li XW,Wang X,Zhao ZQ

    更新日期：2015-06-01 00:00:00

  • The effects of calcium antagonists on extracellular potassium accumulation during global ischaemia in isolated perfused rat hearts.

    abstract：:The effects of equipotent concentrations of diltiazem, verapamil, and nifedipine upon the accumulation of extracellular potassium [K+]out and the left ventricular pressure (LVP) were studied during global ischemia in isolated perfused rat hearts. Measurement of [K+]out and LVP were performed in two series of experimen...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/BF00143532

    authors： Heijnis JB,Coronel R,van Zwieten PA

    更新日期：1991-12-01 00:00:00

  • Low-dose flecainide infusion followed by oral pilsicainide is highly effective and safe for paroxysmal atrial fibrillation.

    abstract：PURPOSE:The aim of this study was to evaluate the efficacy and safety of intravenous infusion of low-dose flecainide (50 mg) followed by oral pilsicainide (50 mg t.i.d.)in patients with paroxysmal atrial fibrillation (AF). METHODS:Thirty-one patients with symptomatic and hemodynamically stable AF lasting less than 48 ...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 临床试验,信件

    doi：10.1023/a:1024368111557

    authors： Nagai S,Takeishi Y,Kubota I

    更新日期：2003-01-01 00:00:00